Lupus clinical trials

Explore recruiting lupus clinical trials.

Recruiting lupus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Lupus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obinutuzumab in Patients with Systemic Lupus Erythematosus

France, Poland, Italy, Czechia, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging, Parallel and Adaptive Study to Evaluate the Efficacy and Safety of Enpatoran in Systemic Lupus Erythematosus and in Cutaneous Lupus Erythematosus (Subacute Cutaneous Lupus Erythematosus and/or Discoid Lupus Erythematosus) Participants Receiving Standard of Care

Spain, Greece, Romania, Poland, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

OPUS-2 - Oral S1P1 Receptor ModUlation in SLE: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy, safety, and tolerability of cenerimod in adult subjects with moderate-to-severe systemic lupus erythematosus (SLE) on top of background therapy

Spain, Germany, Portugal, Poland, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.

Germany, France, Spain, Poland, Bulgaria, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus.

Romania, Ireland, Spain, Germany, France, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Romania, Germany, Hungary, Netherlands, Czechia, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Lupus trials by city

Lupus in Toronto Lupus in Vancouver Lupus in Montreal Lupus in Calgary Lupus in Edmonton Lupus in Ottawa Lupus in Winnipeg Lupus in Quebec City Lupus in Hamilton Lupus in Kitchener Lupus in London Lupus in Halifax Lupus in New York Lupus in Los Angeles Lupus in Chicago Lupus in Houston

Other conditions

Cystic fibrosis Pulmonary fibrosis Sleep apnea Chronic cough Crohn's disease Ulcerative colitis Irritable bowel syndrome Celiac disease GERD Eosinophilic esophagitis Gastroparesis Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis Osteoarthritis Knee osteoarthritis Osteoporosis Sjogren's syndrome Scleroderma Fibromyalgia Psoriasis Eczema (atopic dermatitis) Acne Vitiligo